HC Wainwright Reaffirms “Buy” Rating for Palatin Technologies (NYSEAMERICAN:PTN)

HC Wainwright reaffirmed their buy rating on shares of Palatin Technologies (NYSEAMERICAN:PTN) in a research report report published on Tuesday, Benzinga reports. They currently have a $17.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Palatin Technologies’ Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($2.03) EPS.

Palatin Technologies Price Performance

Shares of NYSEAMERICAN PTN opened at $0.88 on Tuesday. Palatin Technologies has a 52-week low of $0.68 and a 52-week high of $5.65. The firm has a market cap of $17.11 million, a PE ratio of -0.36 and a beta of 1.01.

Palatin Technologies (NYSEAMERICAN:PTN) last announced its quarterly earnings data on Tuesday, October 1st. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Palatin Technologies

An institutional investor recently bought a new position in Palatin Technologies stock. Armistice Capital LLC acquired a new position in Palatin Technologies, Inc. (NYSEAMERICAN:PTN) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 590,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,348,000. Armistice Capital LLC owned approximately 4.29% of Palatin Technologies at the end of the most recent reporting period. 11.50% of the stock is owned by institutional investors and hedge funds.

Palatin Technologies Company Profile

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.